This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
William B. Shockley is shown with co-Nobel Prize in Physics winners Walter H. Brattain (center) and John Bardeen on April 11, 1956.
Document UNITED STATES
2018-08-15 zacks - 1
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney discusses the morning’s top market headlines, including the effect of the Turkish crisis on U.S. stocks, GE’s historic low point, Corona’s new marijuana investment, and earnings from retail giant Macy’s.
STZ.B GEC GE M STZ MCHP CGC BRK.A TWMJF WEED AAPL GNE MS
Tuesday was a positive day for the broad U.S. markets, with all three major indexes positing a solid gain on the day. Crude oil was briefly positive during the session but ultimately ended flat. The S&P 500 sectors were all positive. The most positive sectors were consumer discretionary, financials and materials up 1.0%, 1.0%, and 0.8%, respectively. The worst performing sector was utilities up only 0.
(Aug 15): Smartphone suppliers were among the worst-performing semiconductor stocks Tuesday after two disappointing earnings reports from peers in Asia alarmed investors.
CRUS NVDA MCHP SWKS AMAT AAPL AVGO ADI MS BRCM
Good day everyone and welcome to this Microchip Technology First Quarter and Fiscal Year 2019 Financial Results Conference Call. As a reminder, today's call is being recorded.
Microchip Technology (MCHP - Free Report) came out with quarterly earnings of $1.61 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items.
PLNT GD EPE MCHP
Document UNITED STATES
Document Table of Contents MCHP
CHANDLER, Arizona, Aug. 09, 2018 (GLOBE NEWSWIRE) -- (NASDAQ: MCHP) - Microchip Technology Incorporated, a leading provider of microcontroller, mixed signal, analog and Flash-IP solutions, today reported results for the three months ended June 30, 2018 as summarized in the following table:
CHANDLER, Ariz., Aug. 09, 2018 (GLOBE NEWSWIRE) -- (NASDAQ: MCHP) -- Microchip Technology Incorporated, a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions, today announced that its Board of Directors has declared a quarterly cash dividend on its common stock of 36.40 cents per share. The dividend is payable on September 4, 2018 to stockholders of record on August 21, 2018.
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET